We are live on
!
Find out more
CNCR
ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR
Delisted
CNCR was delisted on the 27th of May, 2025.
19 hedge funds and large institutions have $8.17M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
less ownership
Funds ownership: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
26% less capital invested
Capital invested by funds: $11M → $8.17M (-$2.81M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Holders
19
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$828K | |
| 2 | +$506K | |
| 3 | +$336K | |
| 4 |
FTUS
Flow Traders U.S.
New York
|
+$288K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$124K |
Top Sellers
| 1 | -$4.1M | |
| 2 | -$317K | |
| 3 | -$148K | |
| 4 |
CA
CoreCap Advisors
Southfield,
Michigan
|
-$138K |
| 5 |
Citigroup
New York
|
-$32K |